Rare occurrence of the JAK2 V617F mutation in AML subtypes M5, M6, and M7

被引：45

作者：

Fröhling, S ^{[1
]}

Lipka, DB ^{[1
]}

Kayser, S ^{[1
]}

Scholl, C ^{[1
]}

Schlenk, RF ^{[1
]}

Döhner, H ^{[1
]}

Gilliland, DG ^{[1
]}

Levine, RL ^{[1
]}

Döhner, K ^{[1
]}

机构：

[1] Harvard Univ, Div Hematol, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA

来源：

BLOOD | 2006年 / 107卷 / 03期

关键词：

D O I：

10.1182/blood-2005-09-3644

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1242 / 1243

页数：2

共 9 条

[1] A unifying mutation in chronic myeloproliferative disorders
Goldman, JM
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (17) : 1744 - 1746
[2] JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia
Jelinek, J
Oki, Y
Gharibyan, V
Bueso-Ramos, C
Prchal, JT
Verstovsek, S
Beran, M
Estey, E
Kantarjian, HM
Issa, JPJ
[J]. BLOOD, 2005, 106 (10) : 3370 - 3373
[3] Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders
Jones, AV
Kreil, S
Zoi, K
Waghorn, K
Curtis, C
Zhang, LY
Score, J
Seear, R
Chase, AJ
Grand, FH
White, H
Zoi, C
Loukopoulos, D
Terpos, E
Vervessou, EC
Schultheis, B
Emig, M
Ernst, T
Lengfelder, E
Hehlmann, R
Hochhaus, A
Oscier, D
Silver, RT
Reiter, A
Cross, NCP
[J]. BLOOD, 2005, 106 (06) : 2162 - 2168
[4] On the molecular origins of the chronic myeloproliferative disorders: it all makes sense
Kaushansky, K
[J]. BLOOD, 2005, 105 (11) : 4187 - 4190
[5] The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia
Levine, RL
Loriaux, M
Huntly, BJP
Loh, ML
Beran, M
Stoffregen, E
Berger, R
Clark, JJ
Willis, SG
Nguyen, KT
Flores, NJ
Estey, E
Gattermann, N
Armstrong, S
Look, AT
Griffin, JD
Bernard, OA
Heinrich, MC
Gilliland, DG
Druker, B
Deininger, MWN
[J]. BLOOD, 2005, 106 (10) : 3377 - 3379
[6] Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
Levine, RL
Wadleigh, M
Cools, J
Ebert, BL
Wernig, G
Huntly, BJP
Boggon, TJ
Wlodarska, L
Clark, JJ
Moore, S
Adelsperger, J
Koo, S
Lee, JC
Gabriel, S
Mercher, T
D'Andrea, A
Fröhling, S
Döhner, K
Marynen, P
Vandenberghe, P
Mesa, RA
Tefferi, A
Griffin, JD
Eck, MJ
Sellers, WR
Meyerson, M
Golub, TR
Lee, SJ
Gilliland, DG
[J]. CANCER CELL, 2005, 7 (04) : 387 - 397
[7] Constitutive activation of the JAK2/STAT5 signal transduction pathway correlates with growth factor independence of megakaryocytic leukemic cell lines
Liu, RY
Fan, C
Garcia, R
Jove, R
Zuckerman, KS
[J]. BLOOD, 1999, 93 (07) : 2369 - 2379
[8] HEL CELLS - A NEW HUMAN ERYTHROLEUKEMIA CELL-LINE WITH SPONTANEOUS AND INDUCED GLOBIN EXPRESSION
MARTIN, P
PAPAYANNOPOULOU, T
[J]. SCIENCE, 1982, 216 (4551) : 1233 - 1235
[9] The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes
Steensma, DP
Dewald, GW
Lasho, TL
Powell, HL
McClure, RF
Levine, RL
Gilliland, DG
Tefferi, A
[J]. BLOOD, 2005, 106 (04) : 1207 - 1209

← 1 →